Education
About Us
Working with TipRanks
Follow Us
Jade Biosciences (JBIO)
NASDAQ:JBIO
Total Valuation
Jade Biosciences has a market cap or net worth of $293.64M. The enterprise value is $63.88M.
Market Cap$293.64M
Enterprise Value$63.88M
Share Statistics
Jade Biosciences has 32,626,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32,626,730
Owned by Insiders18.04%
Owned by Institutions0.05%
Financial Efficiency
Jade Biosciences’s return on equity (ROE) is 2.01 and return on invested capital (ROIC) is -116.90%.
Return on Equity (ROE)2.01
Return on Assets (ROA)-1.29
Return on Invested Capital (ROIC)-116.90%
Return on Capital Employed (ROCE)-1.17
Revenue Per Employee0.00
Profits Per Employee-1.39M
Employee Count50
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Jade Biosciences is ―. Jade Biosciences’s PEG ratio is 53.52.
PE Ratio―
PS Ratio0.00
PB Ratio-1.62K
Price to Fair Value-1.62K
Price to FCF-1.67K
Price to Operating Cash Flow-6.49
PEG Ratio53.52
Income Statement
In the last 12 months, Jade Biosciences had revenue of 0.00 and earned -69.63M in profits. Earnings per share was -85.26.
Revenue0.00
Gross Profit-282.00K
Operating Income-74.60M
Pretax Income-69.57M
Net Income-69.63M
EBITDA-69.29M
Earnings Per Share (EPS)-85.26
Cash Flow
In the last 12 months, operating cash flow was -69.71M and capital expenditures -193.00K, giving a free cash flow of -69.90M billion.
Operating Cash Flow-69.71M
Free Cash Flow-69.90M
Free Cash Flow per Share-2.14
Dividends & Yields
Jade Biosciences pays an annual dividend of $2.4, resulting in a dividend yield of 18.72%
Dividend Per Share$2.4
Dividend Yield18.72%
Payout Ratio-17.61%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.38
52-Week Price Change31.76%
50-Day Moving Average9.80
200-Day Moving Average8.90
Relative Strength Index (RSI)67.99
Average Volume (3m)127.19K
Important Dates
Jade Biosciences upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMay 18, 2026
Ex-Dividend DateApr 29, 2025
Financial Position
Jade Biosciences as a current ratio of 5.81, with Debt / Equity ratio of 0.42%
Current Ratio5.81
Quick Ratio5.81
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Jade Biosciences has paid 55.00K in taxes.
Income Tax55.00K
Effective Tax Rate0.00
Enterprise Valuation
Jade Biosciences EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -930.83.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-930.83
EV to Operating Cash Flow-930.83
Balance Sheet
Jade Biosciences has $198.91M in cash and marketable securities with $747.00K in debt, giving a net cash position of $198.16M billion.
Cash & Marketable Securities$198.91M
Total Debt$747.00K
Net Cash$198.16M
Net Cash Per Share$6.07
Tangible Book Value Per Share-$0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Jade Biosciences is $22.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.00
Price Target Upside71.61% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast89.16%